Newsroom

Industry News

12 Dec

Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers

SAN DIEGO, Dec. 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its proprietary NextCollect™ urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers.  NextCollect™ is being offered to both existing contracted clients and...

Read more

11 Dec

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to...

Read more

8 Dec

RegeneRx Releases Annual Letter to Shareholders

ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ —RegeneRx Biopharmaceuticals, Inc. (RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter is focused on updating shareholders on the Company’s product development and commercial partnerships, clinical trials,...

Read more

8 Dec

Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate SAN DIEGO, Dec. 7, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast...

Read more

7 Dec

OncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium

ALAMEDA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today presented positive data from its most recent breast cancer diagnostic test study at the 2017 San Antonio Breast Cancer Symposium (SABCS). The data were presented by Philip...

Read more

5 Dec

Monster Digital Announces Strategic and Legal Developments

SIMI VALLEY, CA, Dec. 04, 2017 (GLOBE NEWSWIRE) — Monster Digital, Inc. (MSDI) (the “Company”) announced today certain strategic and legal developments. The Company announced that it has forwarded Monster, Inc. a notice of termination of that Trademark License Agreement by and between Monster, Inc. and the Company’s wholly-owned...

Read more

5 Dec

Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, announced today that it has received written notification (the “Notification Letter”) from...

Read more

Page 2 of 27412345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address